A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2-DOSE REGIMEN AND A FIRST-IN-HUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A BIVALENT RLP2086-CONTAINING PENTAVALENT VACCINE (MENABCWY) IN HEALTHY SUBJECTS>=10 TO <26 YEARS OF AGE
View DatasetPfizer Inc.
Description
This study is examining safety and immunogenicity of 2 doses of Trumenba administered on a 0-,6- month schedule. This trial is also studying safety and immunogenicity of a meningococcal pentavalent vaccine.
Citations (0)
No citations found
It looks like this dataset has no citations.
Mentions (0)
No mentions found
It looks like this dataset has not been mentioned in any sources.
Metrics Over Time
Publication Details
Subfield
Geriatrics and Gerontology
Field
Medicine
Domain
Health Sciences
Confidence Score
43%
Source
Scholar Data Model
Keywords
Conditions: Meningococcal VaccineInterventions: MenABCWYInterventions: SalineInterventions: rLP2086Interventions: MenACWY-CRM